Cost of Immunotherapy for Lung Cancer in India — Per Cycle, Per Year, and Who It Is Actually For

Most people diagnosed with lung cancer in India do not end up on immunotherapy. It is not used for early-stage disease that surgery removes. It is not the first treatment when the tumour carries an EGFR, ALK or ROS1 alteration. It is a standard option in advanced non-small-cell lung cancer with no targetable alteration, and in small-cell lung cancer alongside chemotherapy.

• Stage decides first — early-stage lung cancer is treated with surgery, and sometimes radiation or chemotherapy. Checkpoint inhibitors enter mainly in advanced or spread disease, as consolidation after chemoradiation in stage 3, and in selected cases around surgery.
• The molecular report decides next — if the tumour carries an EGFR, ALK or ROS1 alteration, targeted oral tablets come first, and NCCN and ESMO guidance does not put checkpoint inhibitors first in that group. In India a large share of lung cancers occur in people who never smoked, where these alterations are more common. Why immunotherapy may not be for you with an EGFR or ALK alteration covers this in detail.
• PD-L1 is a dial, not an on-off gate — the PD-L1 score on the tumour tissue mainly decides whether a checkpoint inhibitor is given on its own or together with chemotherapy. A low score does not by itself rule immunotherapy out. PD-L1 testing in lung cancer explains what the number means.
• Fitness is weighed honestly — performance status, an active autoimmune condition, a previous organ transplant, or ongoing high-dose steroids can all make immunotherapy unsuitable or unsafe.
• Existing lung disease changes the risk — established interstitial lung disease or severe COPD raises the risk of immune-related pneumonitis, and that risk is discussed openly before starting rather than after. See immunotherapy with COPD or existing lung disease.

A cycle is priced by the drug, not by the cancer. As of August 2026, the indicative drug cost for one cycle is roughly ₹50,000 to ₹1,50,000 for a domestically manufactured or biosimilar checkpoint inhibitor, and roughly ₹2,00,000 to ₹4,50,000 for an imported reference product. Day care, chemotherapy and tests add more.

All figures are indicative only, as of August 2026, and are quoted by product class rather than by brand. The real number depends on the product selected, whether the dose is flat or calculated by body weight, the cycle interval, and the centre. Immunotherapy is given as day care at CION centres, so a routine cycle carries no inpatient bed charge. Weight-based versus fixed dosing explains why two people on the same drug can get different bills.

There is no single yearly price, because the length is not fixed in advance. On three-weekly dosing a year is about 17 cycles. That works out to roughly ₹8,50,000 to ₹27,00,000 a year in drug cost for a domestic or biosimilar product, and roughly ₹34,00,000 to ₹81,00,000 for an imported reference product.

These are drug costs only, indicative as of August 2026. Add day-care administration and pre-cycle blood tests for every cycle, and the chemotherapy component for the cycles where it applies. Add a response-assessment scan roughly every eight to twelve weeks — response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION, and runs roughly ₹10,000 – ₹25,000 per scan depending on the scan type, indicative as of August 2026.

Yes, and the gap is wide. A single checkpoint inhibitor is the least expensive immunotherapy route. Adding chemotherapy raises the first four to six cycles, then the bill drops to a maintenance phase. Two immunotherapy drugs together cost the most. Stage 3 consolidation runs to a planned twelve-month ceiling, so that total is knowable in advance.

What decides which regimen you are offered?

The PD-L1 tumour proportion score (TPS) is the main dial once a targetable alteration has been ruled out. It is reported as a percentage of tumour cells staining positive.

Score bands are a guide to how the decision is framed, not a rule that decides your treatment. Histology, stage, symptom burden, organ function and your own preferences all feed into the tumour board discussion. Ask which band your report falls into and what it means for both your regimen and your bill.

Aarogyasri, Ayushman Bharat PM-JAY, CGHS, ECHS and ESI all work to fixed package ceilings. High-cost immunotherapy drugs commonly sit above those ceilings, so cover is often partial or absent. Private insurance usually pays for day-care infusion, subject to sub-limits and pre-authorisation. None of this is a promise of cover.

• Aarogyasri (Telangana and Andhra Pradesh) — lung cancer surgery, radiation and chemotherapy packages are well established. High-cost immunotherapy sits in a different bracket, so ask the scheme desk for the current ceiling in writing.
• Ayushman Bharat PM-JAY — the same package-ceiling logic applies nationally. What the scheme does and does not reach is set out on Ayushman Bharat and immunotherapy coverage.
• CGHS, ECHS and ESI — these run on approved rate lists plus prior approval. The approval step often takes longer than the gap between two cycles, so begin the paperwork before treatment starts rather than between cycles.
• Private health insurance — day-care infusion is payable under most modern policies, but sub-limits, waiting periods, pre-existing-disease clauses and pre-authorisation rules decide what you actually receive. Get the pre-authorisation in writing, not on the phone.
• Manufacturer patient-assistance programmes — several manufacturers run assistance or dose-support programmes in India. Eligibility varies, documentation takes time, and applications usually have to be made before cycle one rather than midway.
• Choosing a domestic or biosimilar product — usually the largest single reduction available on this bill. It is a clinical conversation to have with your oncologist, not a decision to make on your own.
• Relief funds — the Prime Minister's National Relief Fund, the Chief Minister's Relief Fund and district-level assistance can contribute towards cancer treatment. Applications need hospital documentation and an estimate, so start them early.
• Tax relief under Section 80DDB — a deduction is available for specified illnesses including cancer, on a prescribed certificate from a specialist. Details are on tax relief on immunotherapy costs.
• Crowdfunding — widely used for immunotherapy in India, and worth approaching with clear eyes about fees, timelines and privacy. See crowdfunding for immunotherapy.

Lung cancer brings costs no drug price list shows. Breathlessness support, fluid drainage around the lung, and repeated scans are common. Travelling to a day-care centre every three weeks is a real household expense. Budget for these alongside the cycle bill rather than discovering them in month three.

Ask for an itemised estimate before the first cycle that separates the drug from everything else, and ask what happens to that estimate if an immune-related side effect needs treating. A quote that arrives as one number with no breakdown is not yet an estimate you can plan a year around. The hidden costs of immunotherapy lists the lines families most often miss.

Cost only becomes a real question once eligibility is settled, and every cancer gates immunotherapy differently. These pages show how that gate works elsewhere, and how the treatment pathway itself is run at CION.

• Immunotherapy for Melanoma: Why This Cancer Responds Best — the cancer where checkpoint inhibitors were established first, and a useful contrast with how selectively they are used in lung cancer.
• CPS Score in Head and Neck Cancer: What It Decides — a different PD-L1 scoring method for a different cancer, and a clear example of one lab number changing the regimen.
• Immunotherapy for Oesophageal Cancer — another cancer where immunotherapy is added to chemotherapy for a defined group rather than offered to everyone.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, side-effect monitoring and cost counselling run as one pathway.
• Immunotherapy for Lung Cancer: Who Benefits and How Much — the clinical companion to this page, covering what the treatment does and who it is for before cost enters the picture.

Decisions for Healing, Not Billing

Cost is discussed openly at the first consultation — including the option of not starting immunotherapy at all if the numbers do not work for your family.